S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war

Codexis Stock Price, News & Analysis (NASDAQ:CDXS)

$2.47
+0.11 (+4.66%)
(As of 12/1/2023 ET)
Compare
Today's Range
$2.20
$2.49
50-Day Range
$1.50
$2.47
52-Week Range
$1.45
$6.98
Volume
777,681 shs
Average Volume
701,064 shs
Market Capitalization
$172.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.17

Codexis MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
190.1% Upside
$7.17 Price Target
Short Interest
Healthy
4.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
0.83mentions of Codexis in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$55,403 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.93) to ($0.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

350th out of 957 stocks

Industrial Organic Chemicals Industry

7th out of 17 stocks


CDXS stock logo

About Codexis Stock (NASDAQ:CDXS)

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Stock Price History

CDXS Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Benchmark Downgrades Codexis (CDXS)
Q3 2023 Codexis Inc Earnings Call
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Codexis Reports Third Quarter 2023 Financial Results
Codexis earnings: here's what Wall Street expects
Codexis Stock Climbs After Executives Buy Up Shares
Codexis (NASDAQ: CDXS)
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
248
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.17
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+190.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-33,590,000.00
Net Margins
-110.41%
Pretax Margin
-110.15%

Debt

Sales & Book Value

Annual Sales
$138.59 million
Book Value
$1.31 per share

Miscellaneous

Free Float
65,403,000
Market Cap
$172.41 million
Optionable
Optionable
Beta
1.86
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Stephen George Dilly MBBS (Age 63)
    Ph.D., President, CEO & Director
    Comp: $753.61k
  • Mr. Kevin Norrett M.B.A. (Age 50)
    M.S., Chief Operating Officer
    Comp: $507.28k
  • Ms. Margaret Fitzgerald J.D. (Age 52)
    Chief Legal and Compliance Officer, General Counsel & Secretary
    Comp: $300.03k
  • Mr. Sriram Ryali M.B.A. (Age 41)
    Chief Financial Officer
  • Carrie McKim
    Director of Investor Relations
  • Ms. Karen Frechou-Armijo
    Senior VP & Head of Human Resources
  • Dr. Stefan Lutz Ph.D.
    Senior Vice President of Research
  • Mr. Robert Sato M.B.A.
    Ph.D., Senior Vice President of Pharmaceutical Development, Quality & Regulatory














CDXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price target for 2024?

6 Wall Street research analysts have issued 12 month price targets for Codexis' shares. Their CDXS share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $7.17 in the next year. This suggests a possible upside of 190.1% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2023?

Codexis' stock was trading at $4.66 at the beginning of the year. Since then, CDXS stock has decreased by 47.0% and is now trading at $2.47.
View the best growth stocks for 2023 here
.

Are investors shorting Codexis?

Codexis saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,110,000 shares, an increase of 12.3% from the October 31st total of 2,770,000 shares. Based on an average daily volume of 846,800 shares, the days-to-cover ratio is presently 3.7 days.
View Codexis' Short Interest
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06. The biotechnology company earned $9.28 million during the quarter, compared to analyst estimates of $10.96 million. Codexis had a negative trailing twelve-month return on equity of 53.16% and a negative net margin of 110.41%.

What ETFs hold Codexis' stock?

ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Nasdaq Future Gen 200 ETF (QQQS) and ARK Genomic Revolution ETF (ARKG).Inspire Small/Mid Cap ETF (ISMD).

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (6.21%), Baillie Gifford & Co. (5.80%), Ameriprise Financial Inc. (2.56%), Assenagon Asset Management S.A. (2.51%), Jacobs Levy Equity Management Inc. (2.34%) and Federated Hermes Inc. (2.00%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Margaret Nell Fitzgerald, Patrick Y Yang, Sriram Ryali and Stephen George Dilly.
View institutional ownership trends
.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CDXS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -